News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data from INNOVIVE Pharmaceuticals' Oncology Drug Programs to be Presented at the American Society of Hematology 49th Annual Meeting



12/5/2007 12:06:52 PM

NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) announced data that the company believes supports further development of its drug candidates, INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec resistant or intolerant chronic myelogenous leukemia, and INNO-305, a peptide immunotherapy for the treatment of acute myelogenous leukemia, will be presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition. The conference takes place December 8-11, 2007 at the Georgia World Congress Center in Atlanta.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES